ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

ISTH 2022 Congress

July 9-13, 2022. London, England, UK.

View by Title View by Number View Themes
Jump to:  View All • [a] b c d e f g h i j k l m n o p q r s t u v w x y z
  • Abstract Number: OC 75.1

    A 3D microvasculature assay reveals novel sub-cellular dynamics of megakaryocyte endothelial barrier interactions, proplatelet formation and release.

    N. Asquith1, D. Freire1, S. Shelton2, K. Machlus3, R. Kamm2, J. Italiano4

  • Abstract Number: PO0048

    A Cardiac Amyloidosis Presentation: Atrial Mass Versus Thrombus

    F. Alayoubi1, G. Elgohary2

  • Abstract Number: PB0665

    A Case of Discrepant One-stage and Chromogenic Factor VIII Activity Assay in a Patient with a Hemizygous Arg550His Mutation in the F8 Gene

    J. Hancock1, E. Li2, J. Larson1, N. Montanez2, M. Escobar3

  • Abstract Number: PB0708

    A Case of Factor VII Deficiency Presented With Repeated Rectal Bleeding

    ş. şahin1, S. KHUDİYEVA2, A. UNUVAR3, D. TUGCU4, G. TANYILDIZ4, M. BILICI4, Z. KARAKAS4, S. KARAMAN4

  • Abstract Number: VPB0841

    A case of hematidrosis complicated with von Willebrand disease

    M. Takeyama1, S. Furukawa2, K. Ogiwara2, K. Nogami1

  • Abstract Number: VPB1249

    A case report of Inherited platelet function disorders caused by double site mutation of RASGRP2 gene and pedigree analysis

    Q. BIAN1, X. YANG2, D. WANG1, X. ZHOU1

  • Abstract Number: OC 52.4

    A case series examining the safety and efficacy of anticoagulation management in pregnant women with metallic heart valves

    K. White1, L. Millar1, K. Vonklemperer1, L. Bowles1, M. Hogg1, O. Glesa1, R. Howard2, R. Khan1, A. Deaner1

  • Abstract Number: VPB1381

    A Case Series In Pregnant Women Receiving Therapeutic LMWH, Is Monitoring Anti-Xa Levels Necessary?

    S. Chong1, P. Liew2, V. Selvaratnam3, S. Tan2

  • Abstract Number: OC 17.3

    A collaborative study to harmonize thrombin generation assays for measurement of procoagulant activity in immune globulins

    M. Shea1, L. Parunov2, S. Williams3, J. Hogwood3, S. Surov1, Y. Liang1, E. Gray3, M. Ovanesov1

  • Abstract Number: PB1086

    A comparative in vitro study of the coagulation effects of branded versus generic preparations of rivaroxaban

    K. Mangion1, K. Vella2, A. Gatt3, D. Borg Aquilina4, N. Riva5

  • Abstract Number: VPB0636

    A Comparative Study Of Intravenous Bolus Versus Bolus With Continuous Infusion Of Tranexamic Acid To Reduce Blood Loss In Major Surgical Procedures

    N. NEERU1, V. ABRAHAM2

  • Abstract Number: VPB0607

    A Comparison of eNOS-based Platelet Subpopulation Ratios and Platelet VEGF Content within COVID-19

    A. Asgari1, B. Ritchie2, P. Jurasz3

  • Abstract Number: PB0479

    A comparison of thrombin generation ex vivo circuit and in critically ill patients requiring Extracorporeal Membrane Oxygenation

    A. Doyle1, K. Parmar2, N. Gooby2, K. Breen3, N. Barrett2, A. Retter1, B. Hunt1

  • Abstract Number: PB0484

    A comparison study of ROTEM® Sigma and ROTEM® Delta in a major tertiary hospital

    N. Modica1, L. Kaminskis1, M. Anderson1, S. P'ng2, D. Pepperell2

  • Abstract Number: OC 56.1

    A Cross-Ancestry Meta-Analysis of Venous Thromboembolism Genetic Associations

    F. Thibord1, D. Klarin2, D. Chasman3, M. Teder-Laving4, E. Goode5, K. Hveem6, A. Martinez-Perez7, J. Emmerich8, X. Jouven9, K. Ito10, G. Cuellar Partida11, J. Haessler12, J. Hansen13, A. van Hylckama Vlieg14, P. Morange15, C. Kabrhel16, D. Tregouet17, S. Damrauer18, A. Johnson19, N. Smith20

  • Abstract Number: OC 26.2

    A dose-escalation phase 1 clinical trial of autologous iPSC-derived platelets (iPLAT1)

    N. Sugimoto1, J. kanda2, S. Nakamura3, T. Kitano2, S. Shimizu1, A. Shigemasa1, H. Hirai2, M. Minami2, H. Tada2, D. Momose4, K. Koh4, M. Nogawa5, N. Watanabe6, M. Handa6, A. Sawaguchi7, M. Tanaka8, T. Hayashi8, Y. Tani8, A. Takaori-Kondo9, K. Eto3

  • Abstract Number: PB1239

    A Familial Case of MYH9 Gene Mutation Associated with Impaired Platelet Functionality and Structural Alterations

    S. Safiullina1, N. Evtugina1, I. Andrianova1, R. Khismatullin1, O. Kravtsova1, A. Khabirova1, C. Nagaswami2, A. Daminova1, A. Peshkova3, J. Weisel4, R. Litvinov5

  • Abstract Number: PO0012

    A frequency of anti-PF4/heparin antibodies and LA in patients with COVID-19

    T. KIM1, S. Namgoong2, M. Choi2, H. Kim3, S. Jang4

  • Abstract Number: OC 37.4

    A humanized mouse model to assess the therapeutic potential of IdeS in hemophilia A with inhibitors

    M. Bou Jaoudeh1, V. Daventure2, S. Delignat2, J. astermark3, H. Lévesque4, V. Proulle5, S. Lacroix-Desmazes6

  • Abstract Number: PB1113

    A method for measuring chromogenic factor VIII activity unbiased by the presence of the bispecific antibody Emicizumab

    A. Weber, M. Billwein, A. Engelmaier, C. Zlabinger, G. Schrenk

  • Abstract Number: OC 49.3

    A microfluidic model to study the initiation of venous thrombosis

    L. Mereweather1, J. van Batenburg-Sherwood1, J. Ahnström1, I. Salles-Crawley2, J. Crawley1

  • Abstract Number: PB0051

    A Multicenter Cohort Study of COVID-19 Associated Venous Thromboembolism in Admitted Patients Followed Longitudinally 3-Months After Discharge

    C. Drury1, C. Lai2, G. Misselbrook3, A. Al Zaki2, G. Bhangu4, M. Conroy5, L. Eadie4, D. Kumar6, C. Li5, D. Manhas5, N. Singh4, J. Yuan4, A. Lee2, T. Wan7

  • Abstract Number: OC 13.5

    A Multicenter Randomized Clinical Trial of Modulation of Host Thromboinflammatory Response in Hospitalized Patients with COVID-19: The DAWn-Antico study

    M. Engelen1, J. Wauters1, J. Gunst1, C. Wouters1, C. Vandenbriele1, S. Rex1, M. Thomeer2, T. Fivez2, D. Mesotten2, D. Ruttens2, L. Heytens3, P. Verhamme4, T. Vanassche5

  • Abstract Number: VPB0141

    A near real-time surveillance algorithm to identify in-hospital VITT cases

    S. Williams, S. Sivapalaratnam, S. Vohra, P. Johnstone, A. Pentony, C. Gutteridge

  • Abstract Number: PB0666

    A new FVIII chromogenic assay with bovine FX is sensitive enough for the diagnosis of severe haemophilia A.

    M. Jacquemin1, J. Toelen2, K. Peerlinck2, P. Verhamme3, C. Van Laer4

  • Abstract Number: OC 44.3

    A new mouse model of impaired fibrin α-chain crosslinking shows increased venous thrombembolism

    C. Duval1, T. Feller2, H. mcPherson1, R. Ariëns3

  • Abstract Number: PB0804

    A new type 1 von Willebrand Disease (VWD) characterized by increased clearance of von Willebrand Factor (VWF) due to the heterozygous p.P1127S mutation: clinical phenotype and pathogenic mechanisms.

    M. Tardugno1, M. Sacco1, R. De Cristofaro1, S. Lancellotti2, F. Bernardi3, M. Pinotti3, A. Branchini4, B. Giusti5, G. Castaman6

  • Abstract Number: OC 41.5

    A novel and unique mechanism of αIIbβ3 regulation in platelets

    C. Kusch1, D. Stegner2, D. Johnson3, M. Meub4, P. Nurden5, C. Gross6, D. Semeniak6, J. Schenk7, M. Bender8, T. Vögtle9, K. Heinze7, M. Sauer10, A. Nurden5, B. Nieswandt8

  • Abstract Number: PB0295

    A Novel Assay to Investigate Thrombogenesis in TTP Patients

    A. Constantinescu-Bercu1, R. de Groot1, C. Vendramin1, R. Sivera1, C. Capelli1, K. Vanhoorelbeke2, M. Scully3

  • Abstract Number: PB1186

    A novel chemiluminescent-based Thrombin Generation Assay for near-patient monitoring.

    L. van Engelshoven1, C. van de Ridder2, D. Steeghs1, M. van Geffen1, C. van 't Veer1, W. van Heerde1

  • Abstract Number: PB0711

    A novel homozygous KLKB1 missense variant causative of severe Prekallikrein deficiency.

    M. Mitchell1, R. Wheeler2, J. Cutler2, G. Ling3

  • Abstract Number: PB1001

    A Novel Human Factor VIIa Chimera with Increased Tissue Factor-Independent Hemostatic and Anti-Inflammatory Activities

    A. Fager1, M. Hoffman2, D. Monroe3

  • Abstract Number: VPB1116

    A novel material for the improvement of HIT detection

    L. Chen1, H. Nguyen2

  • Abstract Number: OC 10.3

    A novel model of RUNX1-haploinsufficient (RUNX1Lo): Human megakaryocytes infused into mice further characterizes this defect and identifies potential therapeutics

    K. Lee, H. Ahn, M. Poncz

  • Abstract Number: PB1111

    A novel prothrombin R533Q variant in patient with recurrent venous thrombosis

    C. Van Laer1, K. Freson2, R. Lavend'homme2, V. Muczynski3, K. Peerlinck4, C. Thys2, M. Jacquemin5

  • Abstract Number: PB0334

    A novel R1162S variant in MYH9 alters the biochemical interactions and dynamics of NMMHC-IIA, induces severe macrothrombocytopenia and perturbs leukocyte function and cellular coherence

    C. Llorente-González1, M. Millán-Salanova1, A. Marin-Quilez2, L. Díaz-Ajenjo2, S. Santos-Mínguez2, C. Miguel-García2, R. Benito2, J. González-Porras3, J. Rivera4, M. Vicente-Manzanares1, J. Bastida5

  • Abstract Number: PB0810

    A novel role for subtle enhanced VWF clearance in Low VWF pathogenesis highlights limitations of VWFpp/VWF:Ag ratio assessment of clearance.

    D. Doherty1, M. Byrne2, M. Nolan3, J. O'Sullivan4, K. Ryan5, N. O'Connell6, S. Haberichter7, P. Christopherson8, J. Di Paola9, P. James10, M. Lavin11, J. O'Donnell12

  • Abstract Number: PB1057

    A novel, easy-to-use ADAMTS13 activity assay using a fiber-optic surface plasmon resonance biosensor for diagnosis of thrombotic thrombocytopenic purpura

    Q. Bonnez1, E. Tellier2, G. Kaplanski3, C. Tersteeg4, S. De Meyer4, K. Vanhoorelbeke4

  • Abstract Number: OC 65.3

    A Phase 2 Trial Evaluating the Safety and Antithrombotic Efficacy of AB002, a First-in-class Protein C Activator in End-stage Renal Disease Patients on Heparin-free Hemodialysis

    N. Verbout1, C. Lorentz1, B. Markway1, M. Wallisch1, J. Shatzel2, E. Tucker1

  • Abstract Number: LB 01.1

    A Phase 3 study (ATLAS-PPX) to evaluate efficacy and safety of fitusiran, an siRNA therapeutic, in people with haemophilia A or B who have switched from prior factor or bypassing agent prophylaxis

    G. Kenet1, B. Nolan2, B. Zulfikar3, B. Antmen4, P. Kampmann5, T. Matsushita6, C. You7, K. Vilchevska8, C. Bagot9, A. Sharif10, F. Peyvandi11, G. Young12, C. Negrier13, T. Quan14, S. Poloskey15, C. Sussebach16, F. Shammas17, S. Andersson18, B. Mei18, K. Kavakli19

  • Abstract Number: PB0045

    A pilot, open-label, phase II clinical trial of nebulised recombinant tissue-plasminogen activator in patients with COVID-19 acute respiratory distress syndrome: the PACA trial

    P. Chowdary1, B. Agarwal2, S. Bhagani3, M. Lipman4, K. Gomez5

  • Abstract Number: PB0030

    A Population Cohort Study to Evaluate the Risk of Ischemic Stroke Among Individuals with a New Diagnosis of Cancer Compared to Matched Cancer-Free Controls: Impact of Prior Stroke History

    D. Siegal1, J. Cerasuolo2, M. Carrier3, P. Gross4, M. Kapral5, R. Lun6, M. Shamy6, R. Sutradhar5

  • Abstract Number: OC 47.4

    A Post Hoc Analysis of Individuals With Severe Hemophilia A and Inhibitors From the PUPs A-LONG Study

    M. Carcao1, M. Schiavulli2, R. Kulkarni3, P. Rendo4, M. Foster5, E. Santagostino6, S. Casiano5, C. Königs7

  • Abstract Number: PB0673

    A Post-authorization Safety Surveillance Study To Report Clinical Experience With Purified FIX Concentrate in Pediatric Patients With Hemophilia B

    Z. Igrutinović1, L. Hooimeijer2, K. Kentouche3, J. Botha4, P. Turecek5, M. Kokot-Kierepa6, H. Gazda7

  • Abstract Number: PB1091

    A potential suitable alternative to Triton-X-100 for use in sample preparation for platelet nucleotide analysis

    A. McCormick, A. Culhane, E. Bromidge

  • Abstract Number: PB0155

    A potential use of leukocyte-platelet rich fibrin secretome to improve wound healing and bone regeneration

    L. Hermida-Nogueira1, J. Blanco2, J. Reseland3, Á. García1

  • Abstract Number: PB0552

    A Probable Therapeutic for a Child with Inherited Protein S Deficiency

    V. Pereira1, L. Thangada2, M. khosla3, r. majumder4

  • Abstract Number: PB0822

    A quantitative evaluation of high-molecular forms of von Willebrand factor multimers in children’s with different types of vWD.

    A. Poletaev1, E. Seregina1, N. Karamian1, D. Fedorova1, A. Pshonkin1, S. Plyasunova1, P. Zharkov2

  • Abstract Number: PB0933

    A randomized clinical trial to evaluate the effect of rosuvastatin with enoxaparin on circulating tissue factor extracellular vesicles following ovarian cancer surgery

    A. Osataphan1, R. Patell2, R. Rosovsky3, P. Elavalakanar1, A. Bregar4, A. Ramos4, L. Garrett1, S. Ren5, D. Neuberg5, M. Shea1, J. Zwicker2

  • Abstract Number: VPB1220

    A rare case of chronic immune thrombocytopenia with autoantibodies inhibiting platelet aggregation. Effects of romiplostim.

    N. Tsvetaeva1, O. Nikulina1, S. Vasiliev2, S. Khaspekova3, A. Mazurov3

  • Abstract Number: VPB0721

    A Rare Case of Factor XII Deficiency Manifesting as bleeding disorder

    A. KESSIRA, A. AMIRECHE, H. BROUK

  • Abstract Number: VPB0315

    A rare case of thrombosis with ITP

    L. Hambardzumyan, N. Sargsyan1, G. Tamamyan2, A. Harutyunyan3, I. Karapetyan4, N. Yeghiazaryan5, L. Minasyan5, A. Voskanyan6, H. Khachatryan6

  • Abstract Number: PB1090

    A re-visit of the Pre-Kallikrein (Fletcher trait) assay to optimise for laboratory use

    A. McCormick

  • Abstract Number: VPB1221

    A retrospective analysis of 45 cases of HIV-associated thrombocytopenia in a single center over ten years

    y. tan1, L. Che1, H. Bi1, S. Fan2, H. Min2, Z. Zeping3

  • Abstract Number: PB0685

    A Retrospective Database Analysis Study to Evaluate Disease Burden and Treatment Patterns Among Patients With Hemophilia A in China

    X. Song1, W. Liu2, F. Xue2, Y. Yang2, S. Sun3, J. Zhong4, Y. Liu2, J. Shi2, L. Zhang2, E. Wu4, R. Yang2

  • Abstract Number: PB0054

    A role for Von Willebrand Factor-ADAMTS13 axis imbalance and abnormal angiogenesis in Long COVID syndrome

    H. Fogarty1, S. Ward2, L. Townsend3, E. Karampini2, S. Elliott4, M. Byrne5, C. Bergin3, J. O'Sullivan6, I. Martin-Loeches7, P. Nadarajan8, C. Bannon3, R. Preston9, A. Rehill2, C. Ni Cheallaigh3, J. O'Donnell2

  • Abstract Number: PB0806

    A screening assay for type 2B von Willebrand factor variants using an ELISA assay with ristocetin and a recombinant wild-type glycoprotein Ib.

    P. Colpani1, L. Baronciani1, G. Cozzi1, M.T. Pagliari2, A. Cairo3, E. Biguzzi4, F. Peyvandi5

  • Abstract Number: PB1063

    A sensitive and user-friendly method for quantifying VWF collagen binding (VWF:CB) using a fiber optic – surface plasmon resonance biosensor

    B. Calcoen1, M. Jacquemin2, C. Tersteeg3, K. Vanhoorelbeke3, S. De Meyer3

  • Abstract Number: PB1107

    A specific threshold for ELISA detection of Von Willebrand alloantibodies in patients diagnosed as type 3 von Willebrand disease.

    E. Jeanpierre1, M. Desvages2, F. Lassalle2, S. Susen3

  • Abstract Number: VPB0695

    A study of mood state using POMS2 in hemophilia patients

    A. Nakao1, J. Yamanouchi1, K. Kawabe2, T. Hato1, K. Takenaka2

  • Abstract Number: VPB0572

    A study of the stability of fibrinogen and FXIII levels and microbial integrity of pooled cyroprecipitate stored at 1-6°C and 20-24°C for up to 120 hours

    H. Kaur1, A. Ang1, S. Chua1, P. Shu1, C. Tan2, W. Wong2

  • Abstract Number: PB0826

    A Systematic Review of Acquired von Willebrand Syndrome Associated With Cardiac Disorders: Epidemiology, Disease Burden, and Management

    P. Du1, R. Bharali2, S. Sun1

  • Abstract Number: PB0827

    A Systematic Review of Acquired von Willebrand Syndrome Associated With Non-Cardiac Diseases: Epidemiology, Disease Burden, and Management

    P. Du1, R. Bharali2, S. Sun1

  • Abstract Number: VPB1378

    A systematic review of factors associated with non-adherence to the use of coumarin derivatives or direct oral anticoagulants

    W. Freitas Nunes De Sousa1, N. Sernizon Guimarães1, C. Costa Viana1, P. Machado1, A. Fonseca Medeiros1, M. Sousa Vianna1, R. Pedra De Souza1, C. Margotto Bartollo1, M. Praxedes2, M. Parreiras Martins1

  • Abstract Number: PB0298

    A Systematic Review of the Current Epidemiology of Immune-Mediated and Congenital Thrombotic Thrombocytopenic Purpura caused by Severe ADAMTS13 Deficiencies

    P. Du1, T. Cristarella2, Y. Moride3

  • Abstract Number: VPB1192

    A teenage boy with severe hemophilia A with inhibitors on Emicizumab prophylaxis presenting with hyphema

    J. He1, Z. Khademi2, N. Rodriguez3

  • Abstract Number: PB0988

    A TEG-guided treatment algorithm for major surgical bleeding

    S. Dawson1, A. Cain2

  • Abstract Number: PB1322

    A ten-year Australian experience of splanchnic vein thrombosis

    J. Oktaviana1, B. Lui1, P. Ho2, H. Lim1

  • Abstract Number: OC 48.2

    A TEN-YEAR REVIEW OF THE IMPACT OF TRANSITION FROM WARFARIN TO DIRECT ORAL ANTICOAGULANT– HAS VTE TREATMENT BECOME SAFER?

    B. Lui1, B. Wee1, A. Kwok2, J. Lai2, Z. Khattak3, C. Donarelli3, P. Ho4, H. Lim1

  • Abstract Number: PB1406

    A Tertiary Centre Experience of Late Amniocentesis in Obstetric Management of Women with Inherited Bleeding Disorders

    B. Madan1, J. Cutler2, G. Gray3, S. Sankaran4, M. Mitchell5

  • Abstract Number: OC 36.4

    A Tethered Artificial Protease Reveals the Location of Key Regulatory Motifs in Factor V

    F. Ayombil1, R. Toso1, R. Camire2

  • Abstract Number: PB1365

    A Tool Integrated in the Electronic Health Record to Guide Proper Decision-Making Regarding Peri-Endoscopic Anticoagulant Use

    A. Plender1, L. Faber2, S. Graumans1

  • Abstract Number: PB0211

    A translational analysis of immune components in peripheral blood from severe hemophilia A patients treated with TAK-754, an AAV8 vector with a codon-optimized B-domain–deleted factor VIII transgene

    J. Chapin, M. Ayash-Rashkovsky, J. Kenniston, M. Wagoner, Q. Wang

  • Abstract Number: OC 76.2

    A zebrafish model of dysfibrinogenemia caused by hotspot mutations in the human fibrinogen gamma chain

    R. Fish1, M. Richard2, M. Neerman-Arbez3

  • Abstract Number: OC 12.2

    AAV mediated CRISPR/Cas9 based therapeutic gene-editing with a bypass coagulation factor in a murine model of hemophilia.

    P. Sarangi1, S. Bammidi1, R. Sambasivan2, G. Jayandharan1

  • Abstract Number: PB0927

    Abelacimab does not influence the effects of two commonly used antiplatelet agents in vitro

    Y. Khder1, S. Cote2, P. Hoffmann3, D. Bloomfield4

  • Abstract Number: PB0925

    Abelacimab has no effect on platelet aggregation induced by TRAP-6 and collagen

    Y. Khder1, S. Cote2, P. Hoffmann3, D. Bloomfield4

  • Abstract Number: PB0548

    Abelacimab, a Factor XI/XIa Antibody Inhibits Clotting in Hemodialysis Circuits Ex Vivo

    K. Kovacevic1, C. Schörgenhofer2, G. Langer2, Y. Khder3, B. Jilma2, J. Grafeneder4

  • Abstract Number: VPB1344

    ABO blood group and factor viii level as risk factors for idiopathic venous thromboembolism.

    A. Diaz1, M. Vazquez2, M. Ordoñez2, F. Neria2, J. Cachá2, M. Gomez2

  • Abstract Number: VPB1314

    ABO blood group as an additional risk factor for venous thromboembolism

    E. Ristovska1, T. Makarovska Bojadjieva1, S. Useini1, E. Velkova1, E. Petkovic1, V. Dejanova Ilijevska1, J. Trajkova1, L. Ismaili2, M. Tashkovska3

  • Abstract Number: PB0604

    Abridging Molecular System Network of COVID-19 and Thrombosis

    M. Hussain1, A. Amanullah1, N. Jabeen2, B. Kantarcioglu3, F. Siddiqui3, J. Fareed3

  • Abstract Number: OC 33.3

    Absence of Hypercoagulability after nCoV-19 Vaccination: an observational longitudinal study

    C. Simion1, E. Campello2, C. Bulato1, L. Spiezia3, D. Tormene4, C. Radu1, S. Gavasso1, N. Perin1, M. Sartori3, P. Simioni5

  • Abstract Number: OC 58.2

    Absence of Protein Tyrosine Phosphatase-1 in Endothelial Cells Promotes Venous Thrombosis by Mechanisms Involving Extracellular Vesicles

    K. Zifkos1, M. Bochenek2, D. Pedrosa2, R. Gogiraju3, S. Robert4, L. Panicot-Dubois4, W. Ruf5, P. Poncelet6, C. Dubois4, K. Schäfer1

  • Abstract Number: PB1083

    Accuracy Of The Hyphen Zymutest IgG ELISA Assay For Anti-Platelet Factor 4 Antibody Detection After ChAdOx1 nCov-19 Vaccination In Diagnosing Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT)

    E. Leitinger1, J. Clifford1, M. Parker1, A. Iacobelli1, P. Sung1, V. CHEN2, T. Brighton3, F. Passam4, L. Clarke5, H. Tran6, S. Chunilal1

  • Abstract Number: PB0989

    Acquired Factor V Inhibitor In a Patient With Metastatic Cancer

    D. Dhami1, P. Changizzadeh2, C. Solowiej Singh3, S. Dhami4, S. Muttana5

  • Abstract Number: PB0990

    Acquired FXI deficiency (aFXIdef) in a HIV + patient with SLE. Alternative evolution to lupus Anticoagulant (LA) during immunosuppressive therapy.

    C. Seehaus1, M. Lopez2, L. Barrera3, P. Quiñones Maffassanti4, L. Ferreyra Garrott5, V. Privitera6, F. Chuliber7, D. Penchasky8, E. Viñuales8, J. Arbelbide8, M. Martinuzzo9

  • Abstract Number: PB0005

    Acquired haemophilia presenting in a 14-year-old girl

    J. Roganovic

  • Abstract Number: PO0029

    Acquired Hemophilia A: case report

    A. Sarmento1, C. Almeida1, M. Mendes2, L. Borges2

  • Abstract Number: PB0168

    Acquired Hemophilia in four north European countries, a survey of 181 patients

    R. Lindahl1, A. Leithinen2, V. Nummi3, T. Szanto4, L. Hiltunen5, A. Olsson6, A. Glenthoej7, R. Chaireti8, I. Vaide9, E. Funding10, E. Zetterberg11

  • Abstract Number: PB0241

    Acquired Inhibitors: Two Case Studies in Pediatrics

    J. Jain1, M. de La Maza2, L. Truscott2

  • Abstract Number: PB0475

    Acquired von Willebrand Disease in a Patient Undergoing Extracorporeal Membrane Oxygenation

    D. Cibele1, C. Monteiro2, S. Silva3, M. Lopes4, L. Gonçalves5, S. Teixeira6, I. Machado1, M. Carvalho5, R. Roncon-Albuquerque7, C. Koch5

  • Abstract Number: PB1431

    Acquired von Willebrand syndrome in essential thrombocythemia patients referred to special coagulation laboratory of Iranian Blood Transfusion Organization (IBTO)

    A. Rajabi1, M. Ahmadinejad2, S. Ebrahimi3, M. Mojtabavi Naeini4, S. Riahi4, R. Shamriz4, P. Eshghi

  • Abstract Number: VPB0003

    Acquired von Willebrand syndrome in patients with monoclonal gammopathy: a single centre experience.

    M. Costa-Pinto1, M. Fernández2, N. Rodríguez2, A. Pérez-Rodríguez2, M. Gómez-del-Castillo2, T. Lado2, M. Lopez-Fernandez3

  • Abstract Number: PB0474

    Acquired von-Willebrand-disease in ECMO or LVAD patients: a comparative cohort study

    T. Bajorat1, J. Hildebrandt1, B. Pannholzer2, D. Kowalski1, D. Juhl3, J. Kalbhenn4, A. Kowalski2, B. Zieger5, A. Haneya2, U. Nowak-Göttl1

  • Abstract Number: PO0026

    Activated Clotting Time : Setting Target Values of CPB when Changing from Hemochron Resopnse to i-STAT

    T. KIM1, S. Namgoong2, M. Choi2, S. Jang3

  • Abstract Number: PB0174

    Activated Factor XI as Activator of Thrombin Generation to Increase Assay Sensitivity

    R. Arisz1, T. van Lienden2, R. de Laat-Kremers3, J. Eikenboom4, S. Schols5, M. de Maat6

  • Abstract Number: PB0018

    Activated protein C reduces maladaptive unfolded protein response (UPR) to ameliorate diabetes-accelerated atherosclerosis

    S. Fatima1, I. Gadi2, S. Ambreen1, K. Singh3, A. Gupta3, A. Elwakiel2, S. Krishnan1, A. Methew4, H. Khawaja5, S. Kohli2, B. Isermann2, K. Shahzad2

  • Abstract Number: OC 44.1

    Activation of the Plasma Contact System Triggers the Fat Embolism Syndrome

    S. Konrath1, S. Hemkemeyer1, R. Mailer1, K. Püschel1, B. Ondruschka1, T. Renné2

  • Abstract Number: PO0006

    Activity of some coagulative factors and fibrinolysis in patients with arterial hipertension with concomitant diabetes type 2 depending on the carriIage of MTHFR C677T polymorphic genotypes

    E. Shorikov1, D. Shorikova1, P. Shorikov2, A. Esmaeil2

  • Abstract Number: PB0632

    Activity of some protease inhibitors in patients with arterial hypertension of high risk.

    E. Shorikov1, D. Shorikova1, P. Shorikov2, A. Esmaeil2

  • Abstract Number: VPB0523

    Acute arterial limb ischemia after intake of amphetamine derivatives, report of two cases

    A. Restrepo1, A. Arango2, R. Herrera3, J. Arrieta3

  • Abstract Number: VPB0148

    ADAMTS-13 activity and silent brain infarction in patients with non-ischemic dilated cardiomyopathy

    R. GÓMEZ DE ANTONIO1, P. Martínez-Legazpi2, E. Rodríguez González3, A. Fernández ávila3, G. Pérez Rus4, J. Díez Martín4, J. Bermejo Thomas3, C. Pascual Izquierdo4

  • Abstract Number: PB0600

    ADAMTS13 activity and non-parallel vWF Ristocetin CoFactor activity are associated with severity of COVID-19 infection

    S. MacDonald1, D. White1, S. Cox-Morton1, M. Sharp1, E. Duff1, C. Bridgeman1, T. Edwards1, C. Moore1, E. Vilar2, M. Besser1, E. Symington1, M. Robinson1, W. Thomas1

  • Abstract Number: PB0091

    ADAMTS13 in the diagnosis of the severity of COVID-19 mortality

    L. Slavík1, J. Ulehlova1, P. Bradacova2, M. Jancova3, J. Prochazkova1, A. Hlusi1

  • Abstract Number: PB0218

    Adaptative methods using one-stage and chromogenic substrate assays for the quantitative measurement of Mim8 in human plasma

    N. Martineau1, L. Fauconnier1, N. Roland1, A. Carlo2, T. Hervé3, F. Depasse2, M. Ezban4, L. Nicoud1

  • Abstract Number: PO0044

    Adapted Guideline for the Diagnosis and Treatment of Primary Immune Thrombocytopenia in Children in China: Recommendations External Review

    J. Zhang

  • Abstract Number: PB0777

    Adenovirus-based but not mRNA-based vaccines transiently alter platelet count homeostasis in healthy subjects.

    L. lombardi1, N. Scafa2, S. Cesaroni1, R. Marrapodi3, F. Maiorca4, R. Cangemi1, M. Visentini1, G. Romiti1, B. Corica1, F. Pulcinelli3, M. Venneri1, S. Basili1, L. Stefanini3

  • Abstract Number: PB1131

    Adherence and cost effectively of home based prophylaxis over institutionalised based prophylaxis in patients with Hemophilia (PwH) in Upper Assam

    A. Dutta, D. Boruah, A. Boruah

  • Abstract Number: PB0447

    Adherence and persistence to Direct Oral Anticoagulants (DOACs) in the community following newly diagnosed Venous Thromboembolism (VTE) – a pharmacy-linkage study

    C. Dix1, H. Bortz2, M. da Gama3, M. Treloar3, M. Reynolds3, T. Day4, H. Tran5

  • Abstract Number: VPB0682

    Adherence To On Demand Treatment Regimen And Bleeding Outcome (A Multicenter Nigerian Study)

    T. Nwagha1, H. Okoye2, S. Yuguda3, C. Udo4, D. Gwarzo5, M. Ogunfemi6, N. Osuji4

  • Abstract Number: VPB0681

    Adherence to prophylaxis and bleeding outcome in haemophilia: A multicentre Nigerian study

    T. Nwagha1, H. Okoye2, S. Yuguda3, C. Udo4, M. Ogunfemi5, D. Gwarzo6, O. Nnamdi Joel4

  • Abstract Number: PB0960

    Adherence to thrombophilia testing guidelines and accuracy of thrombophilia work-up: a single-center cross sectional study

    K. Vrotniakaite-Bajerciene1, F. Schmidli2, K. Jalowiec2, H. Broughton2, J. Schneider2, A. Haynes3, J. Brodard2, A. Rovo2, J. Kremer Hovinga4, A. Angelillo-Scherrer2

  • Abstract Number: VPB0633

    Adipokines and insulin resistance in young individuals with various metabolic phenotypes

    V. Chulkov1, N. Vereina2, E. Gavrilova2, E. Lenets2, E. Pankova2, S. Martynov2, S. Sinitsin2

  • Abstract Number: PB0972

    Adjusted D-dimer cutoff levels to rule out pulmonary embolism in patients hospitalized for COPD exacerbation: results from the SLICE trial

    D. Jimenez1, C. Rodriguez1, L. Jara-Palomares2, E. Tabernero3, A. Tenes1, S. Gonzalez1, W. Briceño1, J. Lobo4, R. Morillo1, B. Bikdeli5

  • Abstract Number: PB0294

    Adolescent Thrombotic Thrombocytopenic Purpura is a Serious Disorder Requiring Intense Therapies with Significant Morbidity and Relapse

    C. Cohen1, M. Zobeck2, T. Olmsted Kim2, S. Sartain2, L. Raffini3, L. Srivaths4

  • Abstract Number: VPB1342

    Aetiological profile of inferior veina cava thrombosis

    R. Ben Salah1, F. Mkaouar2, o. Frikha2, F. Frikha2, Z. bAHLOUL3

  • Abstract Number: PB0477

    Age and sex distribution of the prevalence and incidence of hospitalisations and mortality due to bleeding in England 2014-2019

    K. Creeper1, A. Stafford2, S. Choudhuri3, N. Tumian4, K. Breen5, A. Cohen6

  • Abstract Number: PB1295

    Age related differences in monocyte subsets, cytokine patterns and the production of anti-SARS-CoV-2 antibodies during acute COVID-19 – a prospective observational longitudinal study

    A. Pirabe1, S. Heber2, W. Schrottmaier3, A. Schmuckenschlager4, S. Treiber3, D. Pereyra5, J. Santol1, E. Pawelka6, M. Traugott6, C. Schörgenhofer7, T. Seitz3, M. Karolyi8, B. Jilma7, U. Resch1, A. Zoufaly9, A. Assinger3

  • Abstract Number: OC 10.5

    Aging Activates Platelet mTOR to Induce Platelet Hyperreactivity

    I. Portier, B. Manne, Y. Kosaka, F. Denorme, R. Campbell

  • Abstract Number: PB0886

    Alcohol intake including wine drinking is associated with decreased platelet reactivity in a large population sample

    R. Pashek1, B. Nkambule2, M. Chan3, F. Thibord4, A. Lachapelle3, J. Cunha5, M. Chen3, A. Johnson3

  • Abstract Number: OC 22.5

    Allele-selective inhibition of murine von Willebrand factor in vitro and in vivo

    Y. Jongejan1, R. Dirven2, K. Paunovska3, N. Linthorst1, E. Schrader3, K. van der Gouw2, A. de Jong2, J. Dahlman3, B. van Vlijmen2, J. Eikenboom2

  • Abstract Number: PB0158

    AlphaFold and molecular dynamics structure predictions of mutations in serpins: lessons from antithrombin

    P. Garrido-Rodríguez1, M. Carmena-Bargueño2, M. de la Morena-Barrio1, C. Bravo-Pérez3, B. de la Morena-Barrio4, R. Cifuentes-Riquelme1, V. Vicente1, M. Lozano1, H. Pérez-Sánchez2, J. Corral1

  • Abstract Number: VPB0611

    Alteration of circulating ACE2 regulating microRNAs profiles in patients with COVID-19

    Z. Wicik1, C. Eyileten1, J. Jarosz-Popek1, D. Jakubik1, A. Nowak1, M. Wolska2, A. Shahzadi3, D. Martins-Jr4, S. Simões5, J. Siller-Matula6, M. Postula1

  • Abstract Number: VPB0373

    Alteration of circulating platelet-related and diabetes-related microRNAs in individuals with type 2 diabetes: Results from a stepwise hypoglycaemic clamp study

    C. Eyileten1, Z. Wicik1, D. Keshwani1, A. Nowak1, F. Aziz2, F. Aberer2, P. Pferschy2, N. Tripolt2, C. Sourij2, B. Prietl2, F. Prüller2, D. Von Lewinski2, J. Siller-Matula3, M. Postula1, H. Sourij2

  • Abstract Number: VPB0746

    Alterations in Coagulation Profiles and Bleeding Rates in Patients with Acute Myeloid Leukemia/Myelodysplastic Syndrome on Prophylactic Anti-Bacterials

    C. Allen, S. Gautam, A. Pine, A. Zeidan, A. Lee, R. Shallis

  • Abstract Number: VPB0130

    Alterations in the coagulation profile and mortality due to covid-19 during the first and second wave in peruvians: A retrospective cohort in a national reference center.

    R. Pichardo-Rodriguez1, W. Peña-Oscuvilca2, L. cordova-Cueva3, J. DE LA CRUZ-VARGAS4, O. Ruiz-Franco2, F. Garmendia-Lorena2

  • Abstract Number: PB0592

    Altered Fibrin Network Structure and Fibrinolysis in Intensive Care Unit Patients with COVID-19, Not Entirely Explaining the Increased Risk of Thrombosis

    J. de Vries1, C. Visser1, L. Geers2, J. Slotman3, N. van Kleef4, C. Maas5, H. Bax6, J. Miedema7, E. van Gorp8, M. Goeijenbier9, J. van den Akker10, H. Endeman10, D. Rijken2, M. Kruip2, M. de Maat11

  • Abstract Number: PB0303

    Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpura

    L. Kühne1, J. Kaufeld2, L. Völker1, R. Wendt3, U. Schönermarck4, D. Eichenauer5, V. Buxhofer-Ausch6, J. Menne2, P. Brinkkoetter1, P. Knöbl7

  • Abstract Number: PB0324

    Alternative anticoagulant treatment in patients with Heparin Induced Thrombocytopenia (HIT). Experience in a high complexity center according to anticoagulants local availability.

    V. Privitera1, M. Garbarini2, F. Chuliber3, M. Villagra Iturre4, D. Mezzarobba4, D. Penchasky4, E. Viñuales4, J. Arbelbide4, M. Martinuzzo5

  • Abstract Number: PB0641

    Alternative cleavage method of LPXTG motif in group A streptococcus by LPXTGase-like protein has a higher selectivity towards aromatic fourth position residues at the sortase A consensus sequence

    B. Readnour1, Y. Ayinuola2, Z. Liang3, B. Russo3, V. Fischetti4, V. Ploplis5, F. Castellino5

  • Abstract Number: VPB0251

    An Analysis of Factors influencing Survival of Bleeding Patients During First Two Years of Life

    S. Sharma1, D. Padhi2, D. Sahu2, R. Sharma2, A. Goel3

  • Abstract Number: PB0225

    An engineered factor X variant as a novel by-passing agent for hemophilia

    E. Tonetto1, M. Testa1, R. Tarantino2, L. Peretto1, M. Pinotti1, A. Branchini1

  • Abstract Number: OC 12.4

    An Enhanced Hemostatic Factor VIII Variant for Hemophilia A Gene Therapy: Prothrombotic and Immunological Risk Assessment

    A. Sternberg, R. Davidson, C. Martos-Rus, A. Wilhelm, L. George

  • Abstract Number: VPB0253

    An Escalating Treatment Strategy for Children with Chronic Immune Thrombocytopenia

    J. Zhang

  • Abstract Number: OC 09.2

    An Extensional Strain-Sensing Mechanosome Drives Rapid Adhesion-Independent Platelet Activation at Supraphysiological Hemodynamic Gradients

    N. Zainal Abidin1, E. Poon2, C. Szydzik3, M. Timofeeva4, F. Akbaridoust4, R. Brazilek3, F. Tovar Lopez5, X. Ma6, C. Lav4, I. Marusic4, P. Thompson6, A. Mitchell5, A. Ooi4, J. Hamilton3, W. Nesbitt3

  • Abstract Number: PB0707

    An Integrated Clinical and Pathological Approach to Rare Bleeding Disorders

    R. Hargreaves1, P. Thwin1, A. Riddell2, T. Yee1

  • Abstract Number: OC 69.5

    An integrative approach to diagnose heparin-induced thrombocytopenia: development, validation, and implementation of a multivariable prediction model

    H. Nilius1, A. Cuker2, S. Haug3, C. Nakas4, J. Studt5, D. Tsakiris6, A. Greinacher7, A. Mendez8, A. Schmidt9, W. Wuillemin10, B. Gerber11, J. Kremer Hovinga12, P. Vishnu13, L. Graf14, A. Kashev3, R. Sznitman3, T. Backchoul15, M. Nagler16

  • Abstract Number: OC 03.5

    An Integrative Biology Approach to Model the Role of the Feedback Activation of FXI by Thrombin in the Tissue Factor Pathway

    H. Lakshmanan1, A. Estonilo2, S. Reitsma3, A. Melrose3, T. Zheng3, J. Maddala4, D. Gailani5, P. Jurney2, C. Puy3, O. McCarty6

  • Abstract Number: PB1136

    An Observational Study To Evaluate The Impact And Disease Burden In Moderate And Severe Hemophilia From Nursing And Patient Perspective (Study Nurses-Who-Care / ML42270)

    S. García Barcenilla1, E. Álvarez-Martínez2, F. Jaime3, Y. Echarte-Buil4, B. Gago-Caballero5, m. Coca6, I. Guerra6, A. Torres-Ortuño7

  • Abstract Number: VPB0694

    Analysis of emicizumab discontinuation in 10 patients with hemophilia A

    A. Nagao1, T. Yamaguchi2, M. Bingo3, K. Fukutake1

  • Abstract Number: PB0671

    Analysis of F8 Genotypes and Pharmacodynamic and Safety Biomarkers in People with Moderate or Mild Hemophilia A Receiving Emicizumab in the HAVEN 6 Trial

    A. Kiialainen1, C. Negrier2, S. Pipe3, B. Beckermann1, O. Catalani1, C. Schmitt1, C. Hermans4, J. Oldenburg5, M. Lehle1

  • Abstract Number: VPB0698

    Analysis of Low- and Intermediate-dose Prophylaxis of 30 Adult Patients with Severe Hemophilia A in a Single Center in Nanjing

    R. Zhou1, Y. Yuan2, Y. Xu1

  • Abstract Number: OC 36.3

    Analysis of TFPI-protein S anticoagulant function in vivo.

    A. Petri1, P. Sasikumar1, P. Badia Folgado1, D. Jones2, J. Ahnström1, I. Salles-Crawley3, J. Crawley1

  • Abstract Number: PB1433

    Analysis of uncharacterised Von Willebrand’s Disease causing mutations located in the D4 and C-domains: identification of a novel type 2A variant and gain-of-function VWF

    G. Mobayen1, M. Appiah2, M. Laffan3, T. McKinnon4

  • Abstract Number: VPB0997

    Analytical performance of different laboratory methods for measuring susoctog-alpha

    C. Novembrino1, I. Quaglia2, M. Boscolo-Anzoletti3, E. Galbiati3, E. Dosio4, A. Valpreda4

  • Abstract Number: PB0888

    Anaphylactic Shock To A Hematological Disorder Patient During Transfusion Of Platelet Aphaeresis Unit Stored In Platelet Additive Solution: A Rare Case Report

    B. poluru mranikrinda

  • Abstract Number: OC 65.2

    Andexanet alfa is associated with a significant reduction in in-hospital mortality compared to 4F-PCC in a real-world analysis

    P. Dobesh1, C. Coleman2, J. Ulloa3, B. Lovelace4, T. Dettling4, B. Koch4, G. Fermann5

  • Abstract Number: OC 22.1

    Angiopoietin-2 binds to Von Willebrand Factor within Endothelial Cells and after Release from Weibel Palade Bodies and mediates Von Willebrand Factor dependent angiogenesis

    T. McKinnon1, R. Starke2, K. Smith2, G. Mobayen2, K. Paschalaki3, A. Randi1, M. Laffan4

  • Abstract Number: VPB0612

    Angiostatin and Plasminogen Levels as Risk Factors for Mortality in Hospitalized Covid-19 Patients

    A. Franczak1, S. Rathwell2, W. Alemayehu2, P. Jurasz3

  • Abstract Number: PB1123

    Annualised Bleeding Rate and Joint Health: Second Interim Analysis of the Real-world HEM-POWR Study Evaluating the Effectiveness of Damoctocog Alfa Pegol in Patients With Haemophilia A

    M. Reding1, M. Alvarez-Román2, M. Sanabria3, G. Castaman4, M. Janbain5, T. Matsushita6, K. Meijer7, K. Schmidt8, J. Oldenburg9

  • Abstract Number: PB0674

    Annualized Bleed Rates in Severe Hemophilia A After Switch to Emicizumab Based on CHESS II Data, Including an Oversample of Emicizumab Patients

    M. Mancuso1, F. Nissen2, H. Zhang2, E. Ferri-Grazzi3, J. O’Hara4, R. Ofori-Asenso5, K. Moreno2, T. Burke4

  • Abstract Number: PB1139

    Annualized Bleeding Rates in Severe Hemophilia on Prophylaxis in a Real-World Setting

    D. Kraemmer1, B. Bauer2, C. Ay2, I. Pabinger2

  • Abstract Number: VPB0316

    Anti-ADAMTS13 IgG in congenital TTP patients

    I. Mancini1, M. Biganzoli2, A. Cairo3, M. Capecchi4, A. Artoni5, B. Ferrari2, S. Trisolini6, L. Facchini7, G. Giuffrida8, A. De Fanti9, P. Agosti10, F. Peyvandi11

  • Abstract Number: VPB0279

    Anti-factor Xa-based risk stratification of children receiving therapeutic enoxaparin is associated with increased risk of recurrent/progressive thrombosis and hemorrhage: a retrospective cohort study

    W. Bourgeois1, E. Drake2, J. Duzan2, N. Chen3, W. London4, N. Ramesh5, R. Kumar6

  • Abstract Number: PB0164

    Anti-inflammatory effect of archaeolipid nanovesicles on human endothelial cells

    N. Charo1, H. Jerez2, S. Tatti3, E. Romero4, M. Schattner5

  • Abstract Number: OC 33.5

    Anti-PF4 IgG levels in patients with VITT remain high at 7 months following vaccination and can still activate platelets

    S. Montague1, C. Smith2, C. Lodwick3, C. Stoneley4, M. Roberts4, G. Lowe5, W. Lester4, S. Watson1, P. Nicolson6

  • Abstract Number: PB0596

    Anti-SARS-CoV-2 vaccines do not induce a hypercoagulable state in healthy individuals

    L. Garabet1, A. Eriksson2, E. Tjønnfjord3, M. Olsen3, H. Jacobsen2, C. Tøvik Jørgensen2, Å. Mathisen2, M. Mowinckel4, M. Ahlen5, I. Sørvoll5, P. Sandset6, W. Ghanima7

  • Abstract Number: PB1268

    Anti-Thrombotic Effects of the Proteasome Inhibitor Carfilzomib on the Endothelium

    A. Hjazi1, C. Gonzalez-Maroto1, M. Rodriguez Gutierrez1, T. Page1, T. McKinnon2

  • Abstract Number: PB1073

    Anti-Xa and APTT stability in whole blood – a comparison of UFH & LMWH

    P. Gajendra1, C. Wigley1, E. Foxton2

  • Abstract Number: OC 32.3

    Anti-β2-glycoprotein I antibodies cause activated protein C resistance by interfering with Factor V cleavage at Arginine 506

    T. Noordermeer1, S. Chemlal1, J. Molhoek2, R. Schutgens3, M. Limper4, P. de Groot5, J. Meijers6, R. Urbanus1

  • Abstract Number: PB0327

    Antibody-induced procoagulant platelets cause increased thrombus formation in heparin-induced thrombocytopenia

    J. Zlamal1, H. Jaffal2, A. Singh3, L. Pelzl4, K. Weich4, K. Althaus4, T. Backchoul1

  • Abstract Number: OC 10.2

    Antibody-mediated depletion of human CLEC-2 in a novel humanized mouse model

    H. Brown1, S. Beck2, S. Navarro1, S. Watson3, B. Nieswandt4, D. Stegner5

  • Abstract Number: VPB0944

    Anticoagulant associated bleeding risk assessment model for cancer associated thrombosis patients: A systematic review

    G. POENOU1, E. TOLEDANO2, H. HELFER3, L. PLAISANCE2, e. VERSINI2, N. DIAB4, S. DJENNAOUI2, I. Mahe5

  • Abstract Number: PB0431

    Anticoagulant therapy for splanchnic vein thrombosis: an individual patient data meta-analysis

    M. Candeloro1, E. Valeriani2, M. Monreal3, W. Ageno4, N. Riva5, R. Lopez Reyes6, M. Peris7, J. Beyer Westendorf8, S. Schulman9, V. Rosa10, J. LÓPEZ-NÚÑEZ11, J. Garcia-Pagan12, M. Magaz12, M. Senzolo13, A. De Gottardi14, M. Di Nisio15

  • Abstract Number: PB1370

    Anticoagulation Control, Outcomes and Associated Factors in Patients Receiving Warfarin in Long-term care in Africa: A Systematic Review

    T. Tadesse1, G. Temesgen2, D. Yadeta3, L. Chelkaba2, T. Gedif2

  • Abstract Number: PB1196

    Antioxidative capacity of platelets in the pathogenesis of immune thrombocytopenia; Finding the forest for trees

    A. Arshad, S. Mukry, T. Shamsi

  • Abstract Number: PB0076

    Antiphospholipid antibodies in patients with acute ischaemic stroke during the COVID-19 pandemic

    P. Mittal1, M. Efthymiou2, R. Simister3, Z. Sayar4, A. Chandratheva3, D. Werring3, H. Cohen5

  • Abstract Number: PB0414

    Antiphospholipid Syndrome-related Venous Thromboembolism: A Nationwide Study

    H. Hwang1, S. Bang2, J. Lee3, S. Kim3, Y. Kim4, M. Kim5, J. Hong6, H. Yhim7

  • Abstract Number: LB 01.5

    Antiplatelet effects of inhibiting coagulation factor XI in a non-human primate model of atherosclerosis

    H. Vu1, T. Kohs1, J. Pang1, K. Jordan1, T. Zheng1, P. Kievit2, J. Johnson1, M. Wallisch3, M. Hinds1, C. Puy1, C. Lorentz3, E. Tucker4, D. Gailani5, J. Aslan1, J. Shatzel1, O. McCarty6, I. Parra-Izquierdo1

  • Abstract Number: PB0914

    Antithrombin activity and association with risk of thrombosis and mortality in patients with cancer

    C. Englisch1, O. Königsbrügge2, F. Moik3, P. Quehenberger4, M. Preusser5, I. Pabinger6, C. Ay6

  • Abstract Number: OC 67.1

    Antithrombin deficiency and altered heparin responsiveness during veno-arterial extracorporeal life support: a prospective study

    A. Mansour1, M. Berahou2, J. Odot2, A. Pontis3, F. NEDELEC-GAC4, A. Parasido5, F. Reizine6, Y. Launey2, A. Ousmen7, R. Garlantezec7, E. Flecher5, N. Nesseler8, I. Gouin9

  • Abstract Number: PB0547

    Antithrombin deficiency is associated with more compact plasma fibrin clot structure and impaired susceptibility to fibrinolysis

    A. Klajmon1, M. Kopytek2, J. Natorska3, A. Undas1, M. Ząbczyk3

  • Abstract Number: PB0787

    Antithrombotic and prohemorrhagic actions of different concentrations of apixaban in patients exposed to single and double antiplatelet regimens

    J. Martinez-Sanchez1, L. Castrillo2, D. Jerez3, S. Torramade-Moix3, M. Palomo1, G. Mendieta4, U. Zafar5, J. Badimon6, M. Roque4, G. Escolar3, M. Diaz-Ricart7

  • Abstract Number: PB0042

    Antithrombotics and antihistamine use correlated with increased COVID-19 severity. Antithrombotics and antihistamine use correlated with increased COVID-19 severity.

    M. Khan1, V. Chan2, C. Maynard2, I. Asekomhe2, M. Brennan1

  • Abstract Number: PB0268

    Aortic Thrombosis Presenting as Myocardial Infarction in a Child

    K. Nelson McMillan1, D. Patel2, N. Ikeda2, S. Kane3, C. Kriesberg2, V. Dorsey2, F. Yousaf2, N. Hibino4, C. El-Zein2, L. Vricella5

  • Abstract Number: OC 18.5

    APAC Treatment Limits Collar-induced Carotid Atherosclerotic Plaque Development in ApoE-/- Mice

    I. Bot1, A. Jouppila2, L. Delfos1, E. Hemme1, P. Kovanen3, R. Lassila4

  • Abstract Number: OC 62.3

    Apixaban for venous thromboembolism treatment in obese patients with weight >120kg or BMI >40 kg m2

    T. Groves1, M. Rees2, R. Alikhan3

  • Abstract Number: PB0494

    Apixaban plasma levels at time of elective surgery: preliminary data from the DALI study

    E. Camilleri1, P. Shahbabai2, M. Rad3, E. van Dorp4, L. Visser2, S. Cannegieter1, N. van Rein1

  • Abstract Number: VPB1121

    Application of Next-generation sequencing in the study of inherited platelet disorders

    G. Ramil López, I. Tirado, L. Romero, N. Vilalta

  • Abstract Number: VPB1118

    Application of prothrombin time clot waveform analysis to assessment of in vitro effects of anticoagulants on normal plasma

    Y. Fujimori1, M. Wakui2, Y. Ozaki3, E. Osada3, S. Oka3, Y. Kondo4, T. Nakagawa3, S. Nakamura3, H. Katagiri5, M. Murata2

  • Abstract Number: PB0080

    Are drug-drug interactions clinically relevant?. Use of edoxaban concomitant to ritonavir in COVID-19 hospitalized patients with atrial fibrillation

    P. Olivera1, D. Campoy1, C. Velásquez-Escandón2, T. Canals3, K. Flores4, E. Johansson4, C. Hernandez5, O. Benitez5

  • Abstract Number: PB0481

    Are levels of direct anticoagulant at the onset of hip fracture surgery associated with post-surgery bleeding?

    A. Lubetsky1, A. Levi2, R. keshet3

  • Abstract Number: PB1016

    Argatroban Monitoring in Critically Ill Patients and correlation with Thrombin Generation

    G. Scheriau1, C. Schkömmer1, L. Wagner2, N. Binder2, B. Steinlechner3

  • Abstract Number: PB0784

    Arginine-containing peptides exhibit antiplatelet effects in experimental type-2 diabetes mellitus and metabolic syndrome

    M. Grigorjeva, T. Obergan, T. Shubina, L. Lyapina

  • Abstract Number: PB0099

    Arterial and venous thrombosis induced by vaccination with ChAdOx1 nCov-19 (Astrazeneca) against Coronavirus 19 (COVID19)

    A. VILASECA1, E. VALGOLIO2, M. Marchena3, N. Kujta4, B. Franco5, C. Capmany4, S. Pastoriza6

  • Abstract Number: OC 13.1

    Arterial Thromboembolism Risk Assessment Model in Hospitalized COVID-19 Patients

    P. Li1, Y. Lee2, Q. Jehangir2, C. Lin3, G. Krishnamoorthy2, A. Sule2, D. Apala2, A. Halabi2, K. Patel2, D. Wang3, L. Poisson3, G. Nair4

  • Abstract Number: OC 20.2

    Artificial intelligence for the point-of-care ultrasound-based detection of joint effusion in patients with hemophilia

    R. Gualtierotti1, S. Arcudi2, M. Colussi3, S. Mascetti3, G. Cafasso4, E. Biguzzi5, C. Bettini3, F. Peyvandi6

  • Abstract Number: OC 60.5

    Artificial Intelligence in the Prediction of Venous Thromboembolism: A Systematic Review and Pooled Analysis

    T. Chiasakul1, B. Lam2, W. Robertson3, L. Lake3, R. Rosovsky4, I. Vlachos2, J. Zwicker2, R. Patell2

  • Abstract Number: PB0222

    Assay of modified factor VIII is modulated by von Willebrand factor. What should we measure ?

    C. Kluft, M. Verhoek

  • Abstract Number: PB0226

    Assay of the factor VIIIa mimetic, Mim8, using one-stage clotting assay requires a product-specific reference material

    H. Wilmot1, M. Ezban2, E. Gray3

  • Abstract Number: PB0874

    Assessing Circulation Persistence of Human Platelet Products in a NOD-SCID Mouse Model

    B. Kuhn1, K. Moskowitz2

  • Abstract Number: PO0072

    Assessing Coagulation by Rotational Thromboelastometry (ROTEM) in Dabigatran-Anticoagulated Blood

    J. Sokol1, F. Nehaj1, M. Mokan1, J. Zolkova2, L. Linekova1, A. Antosikova1, J. Stasko2

  • Abstract Number: PB0052

    Assessing Endothelial Activation and Risk of Bleeding in patients receiving VV-ECMO supportive therapy for COVID-19 using non-standard laboratory assays

    T. Edwards1, D. White1, S. Cox-Morton1, E. Duff1, M. Sharp1, C. Bridgeman1, M. Kirk1, C. Moore1, M. Besser1, E. Symington1, M. Robinson1, W. Thomas1, S. MacDonald2

  • Abstract Number: VPB0126

    Assessing research collaboration networks and social media use among venous thromboembolism researchers during the COVID-19 pandemic

    D. Karsanji1, J. King2, J. Godley2, D. Siegal3, T. Chan4, G. Le Gal5, M. Carrier6, S. Kahn7, M. Rodger8, N. Langlois9, C. MacGillivray10, A. Garven2, L. Skeith2

  • Abstract Number: VPB0515

    Assessing the cardiovascular risk in patients with Systemic Lupus Erythematosus: QRISK and GAPSS scores head to head

    A. Barinotti, M. Radin, I. Cecchi, S. Foddai, E. Rubini, D. Roccatello, E. Menegatti, S. Sciascia

  • Abstract Number: VPB1019

    Assessing the reversal efficacy of prothrombin complex concentrate (PCC) and andexanet alfa in rivaroxaban-anticoagulated blood: Ex vivo study

    F. Rayatdoost1, K. Deventer1, H. Schöchl2, O. Grottke1

  • Abstract Number: PB0958

    Assessment of 3 new functional antithrombin, protein C and protein S assays

    P. Suchon1, E. Maccary2, P. Morange3

  • Abstract Number: VPB0104

    Assessment of COVID -19 associated coagulopathy and multiple hemostatic markers in patients of upper Egypt.

    A. Abdelaal1, A. Abu-Elfatth2, L. Bakkar3, H. Abd El-Azeem2, H. Hetta2, E. Badawy2

  • Abstract Number: OC 71.5

    Assessment of DOACs in GEriatrics (ADAGE) study: rivaroxaban and apixaban plasma concentrations and thrombin generation profiles in very elderly patients with non valvular atrial fibrillation

    G. FOULON-PINTO1, C. LAFUENTE-LAFUENTE2, G. JOURDI3, J. LE GUEN4, F. TALL5, E. PUYMIRAT4, M. DELRUE6, L. RIVIERE7, F. KETZ8, I. Gouin9, F. Mullier10, P. GAUSSEM11, E. PAUTAS12, T. LECOMPTE13, E. CURIS14, V. SIGURET3

  • Abstract Number: VPB0570

    Assessment of Impact of Metabolites of Edoxaban and Dabigatran on Fibrin and Thrombin Generation Assays

    J. Evrard1, R. Siriez1, V. Maloteau1, J. Dogné2, J. Douxfils3

  • Abstract Number: PB0991

    Assessment of Interference by Emicizumab in the Measurement of Susoctocog Alfa Factor VIII Activity Using a Chromogenic Assay

    L. Pan1, A. Mokdad2, P. Turecek3, M. Robinson4, N. Jain1

  • Abstract Number: PB1015

    Assessment of Quantra Analyzer on life-threating bleeding under oral anticoagulants agents: a pilot study

    D. Teissandier1, C. Lucchini2, J. Bouillon-Minois3, J. Schmidt4, T. Sinegre5, c. Morand6, A. Lebreton7, F. Moustafa4

  • Abstract Number: VPB0520

    Assessment of thrombogenesis activity after endovascular treatment of coronary arteries

    I. Vasilenko1, D. Kassina2, G. Shekhyan2, M. Popov2, Z. Kardashova2

  • Abstract Number: PB0485

    Assessment of Trauma-Induced Coagulopathy Using a Microfluidic Model of Injury at Venous and Arterial Shear Regimes

    S. Shea1, R. Rassam1, R. Fonseca2, M. Canas2, K. Thomas3, K. Bochicchio2, G. Bochicchio2, P. Spinella4

  • Abstract Number: VPB1345

    Assessment Of Venous Thromboembolism Risk Factors In Hospitalized Patients At The University of Nigeria Teaching Hospital, Enugu Nigeria

    E. EZIGBO1, T. Nwagha2, V. NWUZOR3

  • Abstract Number: VPB1429

    Association between a first-trimester retrochorionic hematoma and plasminogen activity level

    N. Tikhonova1, N. Kuznetsova2, A. Milovanov1, E. Goufman1, T. Fokina1, M. Boltovskaya1, N. Nizyaeva1

  • Abstract Number: VPB0204

    Association between platelet receptor genotypes and the bleeding tendency of hemophilia patients

    L. Bury1, H. Kuchi Bhotla2, G. Piroli2, E. Cesari2, E. Falcinelli2, G. Guglielmini2, R. De Cristofaro3, B. Zieger4, P. Gresele2

  • Abstract Number: VPB0942

    Association between RET and BRAF(V600) oncogenic status and risk of venous and pulmonary thromboembolism in patients with papillary thyroid cancer

    D. Katalinic1, I. Aleric2, A. Vcev2, M. Solter3, L. Toetome4

  • Abstract Number: PB0046

    Association between thrombin generation and clinical characteristics in COVID-19 patients

    O. Cohen1, N. Landau1, E. Avishai1, T. Barazani1, I. Budnik2, T. Livnat1, K. Asraf1, R. Doolman3, S. Levy-Mendelovich1, E. Orly1, U. Manor1, E. Meltzer1, G. Segal1, G. Rahav1, G. Kenet4

  • Abstract Number: PB0031

    Association between thromboembolus composition and first pass recanalisation after thrombectomy in ischemic stroke

    S. Staessens1, S. Vandelanotte2, O. François3, E. Boulleaux4, M. Bretzner4, B. Casolla5, D. Corseaux4, L. Puy6, L. Desender1, T. Dewaele3, C. Tersteeg7, K. Vanhoorelbeke7, P. Vanacker8, S. Susen9, C. Cordonnier6, T. Andersson10, S. De Meyer7

  • Abstract Number: PB1233

    Association of Genetic Variability in MRVI1Gene in Patients With Arterial Thrombosis and Platelet Hyperaggregability

    M. Brunclikova1, J. Ivankova2, M. Skerenova2, T. Simurda3, M. Dobrotova1, P. Holly2, L. Stanciakova2, M. Sterankova2, I. Skornova1, P. Kubisz1, J. Stasko1

  • Abstract Number: PB0599

    Association of heme/hemopexin/heme-oxygenase 1 pathway with clinical and laboratory markers of severity in Covid-19

    F. Lima1, C. Peachazepi de Moraes2, M. Silva Barbosa1, B. Bombassaro1, A. Palma1, E. Mansur3, L. Velloso1, E. de Paula3

  • Abstract Number: OC 23.4

    Association of inflammation and coagulation biomarkers with Cerebral Venous Thrombosis Clinical and Imaging characteristics: results from FPCCVT

    P. Billoir1, V. SIGURET2, L. Drouet3, E. Masson Fron4, A. Bagan Triquenot5, i. Crassard6, V. Le Cam Duchez7

  • Abstract Number: VPB1217

    Association of platelet desialylation and circulating follicular helper T cells in patients with thrombocytopenia

    Y. Chen1, L. Luo1, Q. Zhen1, S. Kalayu Yirga1, Q. Shi2, J. Hu1

  • Abstract Number: OC 42.5

    Association of polygenic risk scores for severe mental illness with risk of venous thromboembolism

    R. Strawbridge1, J. Ward1, B. Cullen1, N. Graham1, J. Anderson1, J. Pell1, D. Lyall1, L. Lyall1, D. Smith2, M. Sabater-Lleal3

  • Abstract Number: PB0037

    Association of the FVIII/DD and FvW/DD indices as an indicator of severity and mortality in patients with COVID-19

    B. Ascencio, m. jaime Capetillo, F. Vidal Martínez, M. Castillejos Lopez, p. Martel Palomo, A. Castorena maldonado, l. figueroa Hernández, M. Robledo Díaz, J. Martínez de Rafael, n. Ruíz Gómez

  • Abstract Number: PB0071

    Associations between hemostatic markers and mortality in COVID-19 – compounding effects of amplified coagulation and decreased fibrinolytic activity

    N. Boknäs1, C. Laine2, A. Hillarp3, A. Macwan4, K. Gustafsson1, M. Holmström2, T. Lindahl5

  • Abstract Number: PB0512

    Associations of Platelete P2y12 Receptor Polymorphism with Macroangiopathies in Patients with High Cardiovascular Risk

    D. Shorikova, E. Shorikov, P. Shorikov, A. Esmaeil, O. Khukhlina

  • Abstract Number: VPB1189

    ATHN 16: Safety of Coagulation Factor VIIa (recombinant)-jncw for the Treatment of Bleeding Events in Patients with Congenital Hemophilia A or B with Inhibitors, with or without Prophylactic Treatment

    T. Chrisentery-Singleton1, W. Alexander2, A. Al-Sabbagh3, D. Bonzo4, M. Callaghan5, M. Escobar6, A. Giermasz7, M. Hirsh8, J. Journeycake9, S. Nasr10, R. Pruthi11, D. Quon12, A. Rafique13, M. Reding14, s. Sullivan15, M. Recht16

  • Abstract Number: PB0948

    ATHNdataset Hereditary Antithrombin Deficiency (HAD) Pilot Project (ATHN 12) Registry from the American Thrombosis and Hemostasis Network (ATHN)

    M. DeSancho1, E. Suvar1, J. Santos2, M. Recht3

  • Abstract Number: PB0498

    Atrial Fibrillation: Trends in Prevalence and Antithrombotic Prescriptions in the Community

    L. Joosten1, A. de Boer2, E. van Eerde2, S. van Doorn1, A. Hoes2, M. Bots2, F. Rutten2, G. Geersing2

  • Abstract Number: VPB0635

    Attenuation of Thrombotic Biomarkers in a Hyperlipidaemic Sprague Dawley Rats Model

    I. KWAIFA1, K. Perumal2, H. Bahari3, K. Yong3, Z. Eshak4, S. Balan5, A. Abidin5, F. Ghadi3, L. Kong3, S. NOOR3

  • Abstract Number: PB0489

    Audit of the use of Fibclot (Fibrinogen concentrate) in patients without congenital afibrinogenaemia

    M. Ul-haq1, G. Baidya2, G. Gidley2, E. Horn2, A. Kanny2, J. Tarrant3

  • Abstract Number: VPB0490

    Audit on the use of fresh frozen plasma in a Tertiary Care Hospital

    G. Ene1, M. Raya Hinojosa2, L. Edo Caballero2, A. Carpi Medina2, A. Villaubi Serra2, N. Palo Mauriz2, E. Membrilla Fernandez2, J. Alvarez Garcia2

  • Abstract Number: VPB1224

    Autoimmune mediated hematological disease associated with COVID-19 disease or vaccination: A multi-centre case series.

    C. Wynick, H. Sun

  • Abstract Number: PB0151

    Automated genotyped matching of platelets to prevent alloimmunisation

    N. Gleadall1, R. Fenton2, D. Hart3, P. Winter4, K. Lee5, C. Booth6, L. Walker7, S. Stanworth8, B. Genomics Consortium9, W. Ouwehand10, W. Astle11, S. Sivapalaratnam12

  • Abstract Number: OC 16.5

    Available Risk Scores Modestly Predict Hemorrhage in Patients with Cancer-Associated Thrombosis (CAT)

    K. Sanfilippo1, S. Luo2, B. Gage3

  • Abstract Number: PB0395

    Avidity-dependent differential signaling by CLEC-2 receptors

    S. Kunapuli1, C. Dangelmaier1, J. Kostyak2

Jump to:  View All • [a] b c d e f g h i j k l m n o p q r s t u v w x y z
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2022 John Wiley & Sons, Inc. All Rights Reserved.
Wiley